Thus, the greatest clinical utility of AFP-L3 or DCP has been proposed to be in patients with intermediate AFP values (20–200 ng/mL); in which they have shown to be highly specific for HCC [52]. This evidence concerns the gene AFP and hepatocellular carcinoma.